Spark Therapeutics, Inc. has secured $72.8 million in investment capital from investors. The company, a member of the Roche Group, is dedicated to unlocking the power of gene therapy to accelerate healthcare transformation, driven by a mission to create a world where no life is limited by disease.
At its core, Spark Therapeutics is a fully integrated gene therapy company focused on developing treatments for inherited retinal diseases (IRDs), neurodegenerative diseases, and diseases that can be addressed by targeting the liver, such as hemophilia. Born from scientific innovation and the dedication of healthcare visionaries, Spark has built a comprehensive approach to gene therapy since its founding.
This significant funding round underscores continued investor confidence in Spark Therapeutics' scientific approach and its robust pipeline of potential therapies. The newly raised capital is intended to support the company's ongoing research and development initiatives, further advancing its programs across its key therapeutic areas. It will also enable Spark to continue its commitment to bringing a wide range of expertise to its work, fostering the curiosity and courage needed to reimagine healthcare.
The investment positions Spark Therapeutics to accelerate its efforts in breaking barriers and turning genes into medicine. By strengthening its operational capabilities and expanding its research footprint, the company aims to bring gene therapy to people worldwide. This strategic funding reinforces Spark Therapeutics' vision for a new healthcare paradigm, as it strives to deliver transformative treatments and create a future where life is not limited by disease.
